The combination of an ARSI and a PARP-inhibitor is hypothesized to act synergistically in two ways: (i) slowing or halting tumor growth and progression, (ii) while blocking DNA repair at all major pathways in PCa cells and thus ultimately inducing apoptosis. Here, PARP1 is linked to neoplasm.